Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115297 | 0.96 | TNK2 (0.45) | TNK2HDAC6MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL2115272 | 0.91 | TNK2 (0.42) | TNK2HDAC6MAPTKMT2AHTR7 | |
| SCHEMBL2116066 | 0.87 | HTT (0.42) | TNK2MBTD1L3MBTL3L3MBTL1EGFR | |
| SCHEMBL2114137 | 0.87 | CDK9 (0.43) | TNK2MBTD1L3MBTL3L3MBTL1NOS1 | |
| SCHEMBL2114805 | 0.87 | TNK2 (0.46) | TNK2HDAC6MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL2116118 | 0.87 | HTT (0.46) | TNK2MBTD1L3MBTL3L3MBTL1MAPT | |
| SCHEMBL2116828 | 0.84 | HTT (0.43) | TNK2NOS3NOS1MAPTKMT2A | |
| SCHEMBL2113867 | 0.83 | TNK2 (0.46) | TNK2HDAC6NOS1FGFR1 | |
| SCHEMBL2112548 | 0.83 | CDK9 (0.44) | TNK2NOS3NOS1NOS2 | |
| SCHEMBL2115703 | 0.83 | HTT (0.47) | TNK2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158641-B2 | 2-anilino-4-aminoalkyleneaminopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-2032543-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146977-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | TNK2 195/4885HDAC6 3109/4885MBTD1 2789/4885 |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | TNK2 195/4885HDAC6 3109/4885MBTD1 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.